FDA’s January 2024 mandated boxed warnings for CAR-T therapies HASN’T stifled enthusiasm for further CAR-T development – look at BioNTech cosying up to Autolus!

FDA’s January 2024 mandated boxed warnings for CAR-T therapies HASN’T stifled enthusiasm for further CAR-T development – look at BioNTech cosying up to Autolus!

Despite the FDA mandating just a few weeks ago that all current CAR-T approved therapies must carry a box warning of observed or anticipated secondary malignancies, further development of CAR-T therapies appears to be enthusiastically healthy.  The latest salvo comes from BioNTech hoping to capitalize on Autolus’ USPs – its manufacturing capacity, options to develop and co-commercialise Autolus’ programs and accessing Autolus’ target binders and technologies.

READ THE ARTICLE – https://investors.biontech.de/news-releases/news-release-details/biontech-and-autolus-announce-strategic-car-t-cell-therapy

Share this post